Class action lawsuits and legal investigations are now front and center for ADMA Biologics (ADMA), after several law firms alleged securities fraud related to related party transactions, channel stuffing, and disclosures about business practices.

At a latest share price of $9.90, ADMA Biologics has seen a 7 day share price return of 17.02% and a 90 day share price return of 21.18%, yet the year to date share price return is down 44.63%. Over the longer term, the total shareholder return is down 40.07% over 1 year but up more than 7x over 5 years, which suggests recent momentum is weakening even after the Q2 2026 earnings release and reiterated 2026 guidance.

If these legal headlines have you reassessing your exposure to a single stock, it can help to step back and look at other parts of the market using a focused screener such as 43 healthcare AI stocks.

After a sharp bounce in ADMA Biologics despite lawsuits and investigations now in play, the key issue is whether the current valuation still compensates you for these risks or has already priced in too much optimism.

Most Popular Narrative: 43.8% Undervalued

Against a last close of $9.90, the most followed narrative on ADMA Biologics points to a fair value of $17.60, which implies a sizeable valuation gap that rests on specific growth and margin assumptions.

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.

Want to see what happens when higher output, richer margins, and rising earnings get projected years into the future. The narrative leans on compounding revenue, fatter profit margins, and a valuation multiple that assumes ADMA Biologics keeps executing. Curious which combination of growth, profitability, and discount rate bridges today’s price to that higher fair value.

Result: Fair Value of $17.60 (UNDERVALUED)

However, this upbeat ADMA Biologics narrative still hinges on the successful execution of the yield enhancement process and on avoiding prolonged pressure from larger plasma competitors.

Next Steps

With sentiment on ADMA Biologics split between legal concerns and long term potential, it makes sense to review the facts yourself and move quickly if needed. To see what is driving optimism, take a closer look at the 3 key rewards.

Looking for more ideas beyond ADMA Biologics?

If you are reassessing ADMA Biologics, it can be useful to line up a few fresh ideas so your portfolio is not leaning too hard on a single story.

• Target potential mispricing opportunities by scanning 51 high quality undervalued stocks that may offer stronger fundamentals at prices that still look reasonable.
• Strengthen the foundation of your portfolio by focusing on companies highlighted in the solid balance sheet and fundamentals stocks screener (49 results) so you are not relying on fragile balance sheets.
• Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems and spotting quality businesses before they sit on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.